tbuckley/cabot-search huggingface dataset:
Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation
Authors: Juxiang Cao, Magdalena E. Tyburczy, Joel Moss, Thomas N. Darling, Hans R. Widlund, David J. Kwiatkowski
Journal: Journal of Clinical Investigation (2016)

Tuberous sclerosis complex (TSC) is an autosomal dominant tumor-suppressor gene syndrome caused by inactivating mutations in either TSC1 or TSC2, and the TSC protein complex is an essential regulator of mTOR complex 1 (mTORC1). Patients with TSC develop hypomelanotic macules (white spots), but the molecular mechanisms underlying their formation are not fully characterized. Using human primary melanocytes and a highly pigmented melanoma cell line, we demonstrate that reduced expression of either TSC1 or TSC2 causes reduced pigmentation through mTORC1 activation, which results in hyperactivation of glycogen synthase kinase 3β (GSK3β), followed by phosphorylation of and loss of β-catenin from the nucleus, thereby reducing expression of microphthalmia-associated transcription factor (MITF), and subsequent reductions in tyrosinase and other genes required for melanogenesis. Genetic suppression or pharmacological inhibition of this signaling cascade at multiple levels restored pigmentation. Importantly, primary melanocytes isolated from hypomelanotic macules from 6 patients with TSC all exhibited reduced TSC2 protein expression, and 1 culture showed biallelic mutation in TSC2, one of which was germline and the second acquired in the melanocytes of the hypomelanotic macule. These findings indicate that the TSC/mTORC1/AKT/GSK3β/β-catenin/MITF axis plays a central role in regulating melanogenesis. Interventions that enhance or diminish mTORC1 activity or other nodes in this pathway in melanocytes could potentially modulate pigment production.
Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.
Authors: William Blum, Rebecca Bruner-Klisovic, Shujun Liu, John C. Byrd, Zhongfa Liu, Kenneth K. Chan, Cheryl Kefauver, Lenguyen Huynh, Michael R. Grever, Guido Marcucci
Journal: Blood (2005)
Ultra–High-Dose Opioids With Low Efficacy and Significant Harm—Time to Make a Change
Authors: Paul Guillod, Ellen L. Edens, William C. Becker
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study
Authors: Anita D'Souza, Baldeep Wirk, Mei-Jie Zhang, Jiaxing Huang, Amrita Krishnan, Tomer M Mark, Cristina J. Gasparetto, Parameswaran N. Hari
Journal: Blood (2014)
Inflammatory Cytokine IL-1β Upregulates Hepcidin Expression in Human Hepatoma Cell Lines.
Authors: Katsuya Ikuta, Junki Inamura, Junko Jimbo, Takaaki Hosoki, Motohiro Shindo, Kazuya Sato, Yoshihiro Torimoto, Yutaka Kohgo
Journal: Blood (2005)
Association of FOXO3A Polymorphisms with Hematocrit, LDH and Longevity in Patients with Sickle Cell Anemia from CSSCD, Walk-Phasst, and PUSH Clinical Trials
Authors: Harold T Bae, Paola Sebastiani, Victor R. Gordeuk, Yingze Zhang, Martin H. Steinberg, Gregory J Kato
Journal: Blood (2015)
Peroral endoscopic myotomy: ready for prime time in all achalasia patients?
Authors: Albert Bredenoord
Journal: Endoscopy (2016)

It was 10 years ago that the first endoscopic myotomies, performed in four pigs, were described by Pasricha et al. [1]. Inoue refined the technique, and in 2010 he described in this journal the excellent results of the procedure in the first 17 patients with achalasia; it was the first time the abbreviation POEM was used for peroral endoscopic myotomy [2]. His enthusiasm, the elegance of the technique, and the excellent results have led to a rapid uptake of the technique worldwide. POEM is the first natural orifice transluminal endoscopic surgery technique with the potential to become a routine treatment, albeit for a rare disease.
Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.
Authors: Jennifer R. Brown, John G. Gribben, Yang Feng, Donna Neuberg, Peter Mauch, Lee M. Nadler, Arnold S. Freedman
Journal: Blood (2006)
Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant <i>BCL11B</i>
Authors: Divya Punwani, Yong Zhang, Jason Yu, Morton J. Cowan, Sadhna Rana, Antonia Kwan, Aashish N. Adhikari, Carlos O. Lizama, Bryce A. Mendelsohn, Shawn P. Fahl, Ajithavalli Chellappan, Rajgopal Srinivasan, Steven E. Brenner, David L. Wiest, Jennifer M. Puck
Journal: New England Journal of Medicine (2016)

Severe combined immunodeficiency (SCID) is characterized by arrested T-lymphocyte production and by B-lymphocyte dysfunction, which result in life-threatening infections. Early diagnosis of SCID through population-based screening of newborns can aid clinical management and help improve outcomes; it also permits the identification of previously unknown factors that are essential for lymphocyte development in humans.SCID was detected in a newborn before the onset of infections by means of screening of T-cell-receptor excision circles, a biomarker for thymic output. On confirmation of the condition, the affected infant was treated with allogeneic hematopoietic stem-cell transplantation. Exome sequencing in the patient and parents was followed by functional analysis of a prioritized candidate gene with the use of human hematopoietic stem cells and zebrafish embryos.The infant had "leaky" SCID (i.e., a form of SCID in which a minimal degree of immune function is preserved), as well as craniofacial and dermal abnormalities and the absence of a corpus callosum; his immune deficit was fully corrected by hematopoietic stem-cell transplantation. Exome sequencing revealed a heterozygous de novo missense mutation, p.N441K, in BCL11B. The resulting BCL11B protein had dominant negative activity, which abrogated the ability of wild-type BCL11B to bind DNA, thereby arresting development of the T-cell lineage and disrupting hematopoietic stem-cell migration; this revealed a previously unknown function of BCL11B. The patient's abnormalities, when recapitulated in bcl11ba-deficient zebrafish, were reversed by ectopic expression of functionally intact human BCL11B but not mutant human BCL11B.Newborn screening facilitated the identification and treatment of a previously unknown cause of human SCID. Coupling exome sequencing with an evaluation of candidate genes in human hematopoietic stem cells and in zebrafish revealed that a constitutional BCL11B mutation caused human multisystem anomalies with SCID and also revealed a prethymic role for BCL11B in hematopoietic progenitors. (Funded by the National Institutes of Health and others.).
Absence of STAT1 Signaling in Host Hematopoietic Cells Leads to Enhanced Gvhd Induction and Involves Increased Expression of MHC Class II and Reduced PD-L1 Expression on Dendritic Cells,
Authors: Caisheng Lu, Huihui Ma, Ailing Liu, MeiHua Jin, Shirong Li, Suzanne Lentzsch, Markus Y. Mapara
Journal: Blood (2011)
Early Results of Pentostatin, Cytoxan, Rituximab (PCR) Followed by CAMPATH-H (CA) for the Treatment of Relapse/Refractory Chronic Lymphocytic Leukemia (CLL) in ECOG Protocol E2903.
Authors: Sanford Kempin, N.E. Kay, Z. Sun, C. Secreto, R.C. Tschumper, D.F. Jelinek, S. Smoley, D. Van Dyke, J. Saltzman, S. Rosen, M.S. Tallman
Journal: Blood (2007)
Effect of the Goals of Care Intervention for Advanced Dementia
Authors: Laura C. Hanson, Sheryl Zimmerman, Mi-Kyung Song, Feng-Chang Lin, Cherie Rosemond, Timothy S. Carey, Susan L. Mitchell
Journal: JAMA Internal Medicine (2016)

<h3>Importance</h3> In advanced dementia, goals of care decisions are challenging and medical care is often more intensive than desired. <h3>Objective</h3> To test a goals of care (GOC) decision aid intervention to improve quality of communication and palliative care for nursing home residents with advanced dementia. <h3>Design, Setting, and Participants</h3> A single-blind cluster randomized clinical trial, including 302 residents with advanced dementia and their family decision makers in 22 nursing homes. <h3>Interventions</h3> A GOC video decision aid plus a structured discussion with nursing home health care providers; attention control with an informational video and usual care planning. <h3>Main Outcomes and Measures</h3> Primary outcomes at 3 months were quality of communication (QOC, questionnaire scored 0-10 with higher ratings indicating better quality), family report of concordance with clinicians on the primary goal of care (endorsing same goal as the “best goal to guide care and medical treatment,” and clinicians’ “top priority for care and medical treatment”), and treatment consistent with preferences (Advance Care Planning Problem score). Secondary outcomes at 9 months were family ratings of symptom management and care, palliative care domains in care plans, Medical Orders for Scope of Treatment (MOST) completion, and hospital transfers. Resident-family dyads were the primary unit of analysis, and all analyses used intention-to-treat assignment. <h3>Results</h3> Residents’ mean age was 86.5 years, 39 (12.9%) were African American, and 246 (81.5%) were women. With the GOC intervention, family decision makers reported better quality of communication (QOC, 6.0 vs 5.6;<i>P</i> = .05) and better end-of-life communication (QOC end-of-life subscale, 3.7 vs 3.0;<i>P</i> = .02). Goal concordance did not differ at 3 months, but family decision makers with the intervention reported greater concordance by 9 months or death (133 [88.4%] vs 108 [71.2%],<i>P</i> = .001). Family ratings of treatment consistent with preferences, symptom management, and quality of care did not differ. Residents in the intervention group had more palliative care content in treatment plans (5.6 vs 4.7,<i>P</i> = .02), MOST order sets (35% vs 16%,<i>P</i> = .05), and half as many hospital transfers (0.078 vs 0.163 per 90 person-days; RR, 0.47; 95% CI, 0.26-0.88). Survival at 9 months was unaffected (adjusted hazard ratio [aHR], 0.76; 95% CI, 0.54-1.08;<i>P</i> = .13). <h3>Conclusions and Relevance</h3> The GOC decision aid intervention is effective to improve end-of-life communication for nursing home residents with advanced dementia and enhance palliative care plans while reducing hospital transfers. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01565642
Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells
Authors: Takeshi Harada, Shuji Ozaki, Asuka Oda, Masami Iwasa, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Hironobu Shibata, Akishige Ikegame, Daisuke Tsuji, Kohji Itoh, Masaki Ri, Shinsuke Iida, Yukimasa Shiotsu, Shigeto Kawai, Hisafumi Yamada-Okabe, Toshio Matsumoto
Journal: Blood (2012)
Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd
Authors: Sally Arai, Bita Sahaf, Carol Jones, James Zhender, Robert Lowsky, Samuel Strober, Judith Shizuru, Robert Negrin, Laura Johnston, Ginna Laport, Joanna Schaenman, Janice Brown, Wen-Kai Weng, Renee Letsinger, Ruby Wong, Philip Lavori, David Miklos
Journal: Blood (2008)
A multicenter study on anaphylaxis caused by peanut, tree nuts, and seeds in children and adolescents
Authors: K. Jeong, S.-Y. Lee, K. Ahn, J. Kim, H.-R. Lee, D. I. Suh, B.-Y. Pyun, T. K. Min, J.-W. Kwon, K.-E. Kim, K. W. Kim, M. H. Sohn, Y. H. Kim, T. W. Song, J. H. Kwon, Y. H. Jeon, H. Y. Kim, J. H. Kim, Y. M. Ahn, S. Lee
Journal: Allergy (2016)

Peanut (PN) and tree nuts (TNs) are common causes of anaphylaxis in Western countries, but no information is available in Korea. To feature clinical characteristics of anaphylaxis caused by PN, TNs, and seeds, a retrospective medical record review was performed in 14 university hospitals in Korea (2009–2013). One hundred and twenty-six cases were identified, with the mean age of 4.9 years. PN, walnut (WN), and pine nut accounted for 32.5%, 41.3%, and 7.1%, respectively. The median values of specific IgE (sIgE) to PN, WN, and pine nut were 10.50, 8.74, and 4.61 kUA/l, respectively. Among 50 cases managed in the emergency department, 52.0% were treated with epinephrine, 66.0% with steroid, 94.0% with antihistamines, 36.0% with oxygen, and 48.0% with bronchodilator. In conclusion, WN, PN, and pine nut were the three most common triggers of anaphylaxis in Korean children, and anaphylaxis could occur at remarkably low levels of sIgE.
Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial
Authors: Anna Candoni, Giovanni Martinelli, Cristina Papayannidis, Erica Simeone, Eleonora Toffoletti, Alexia Chiarvesio, Stefania Paolini, Angela Michelutti, Pier Paolo Piccaluga, Filippo Gherlinzoni, Elisabetta Calistri, Michele Gottardi, Giuseppe Visani, Pierpaolo Isidori, Michele Malagola, Barbara Lama, Mario Tiribelli, Daniela Damiani, Domenico Russo, Renato Fanin, Michele Baccarani
Journal: Blood (2008)
Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.
Authors: Santiago Mercadal, Antonio Martinez-Pozo, Francesc Bosch, Eva Gine, Ana Muntanola, Olga Salamero, Gonzalo Gutierrez, Silvia Montoto, Luis Colomo, Elias Campo, Emili Montserrat, Armando Lopez-Guillermo
Journal: Blood (2006)
Fatalities Following Intravenous Use of Sodium Diphenylhydantoin for Cardiac Arrhythmias
Authors: Allen H. Unger
Journal: JAMA (1967)

IN 1950 Harris and Kokernot<sup>1</sup>reported that sodium diphenylhydantoin (Dilantin Sodium) is effective in the treatment of cardiac arrhythmias in the experimental animal. Since then, several reports have been published which demonstrate the efficacy of diphenylhydantoin given intravenously in abolishing arrhythmias in dogs and humans.<sup>2-7</sup> There have been no reported fatalities due to intravenous use of diphenylhydantoin in treating cardiac arrhythmias in humans. The purpose of this report is to present two cases of patients who died following intravenous administration of diphenylhydantoin. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 67-year-old white woman with a 30-year history of diabetes mellitus and a ten-year history of angina pectoris was admitted to the Mount Sinai Hospital on Feb 8, 1966, with an acute myocardial infarction (inferior wall) complicated by pulmonary edema. The pulmonary edema responded to treatment including administration of digitalis. Anticoagulants were also administered. The hospital course was then uncomplicated except
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
Authors: Manish A. Shah, Yung-Jue Bang, Florian Lordick, Maria Alsina, Meng Chen, Stephen P. Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S. Shames, See Phan, David Cunningham
Journal: JAMA Oncology (2016)

Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.
Alternating QRS Complex Morphologic Characteristics in a Man Presenting With Scrotal Edema
Authors: Jin Ge, Christopher Groh, Nora Goldschlager
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group
Authors: Jordi Ribera, Lurdes Zamora, Eulàlia Genescà, Mireia Morgades, Pau Montesinos, Jose Sarra, Ramon Guardia, Inés Gómez-Seguí, Marta Pratcorona, Jordi Esteve, Josep F. Nomdedeu, Salut Brunet, Lourdes Escoda, Mar Tormo, Maria Collado, Joaquin Martínez, Jesus Maria Hernández-Rivas, Pilar Martinez-Sanchez, Marcos González, José González-Campos, Pablo Trujillo, Pere Barba, Isabel Granada, Francesc Sole, Fuensanta Milla, Evarist Feliu, Josep-Maria Ribera
Journal: Blood (2014)
Multicenter Cardiovascular Studies and Trials
Authors: Arthur J. Moss, Jesia Benhorin, Thomas Bigger, Poul Eric Block-Thomsen, Monty Bodenheimer, Mary Brown, Robert Case, Edward M. Dwyer, Shirley Eberly, Joseph Fleiss, Charles Francis, John Gillespie, Robert Goldstein, Henry Greenberg, Mark Haigney, Helmut Klein, Ronald Krone, Valentina Kutyifa, Edgar Lichstein, Emanuela Locati, Frank Marcus, Arthur J. Moss, David Oakes, Charles Odoroff, Daniel Ryan, Wojciech Zareba, Christopher Beck, Mary Brown, David Cannom, James Daubert, Mark Estes, Ilan Goldenberg, Henry Greenberg, Jack Hall, Stephen Hammes, David Huang, Helmut Klein, Reinoud Knops, Michael Kosiborod, Valentina Kutyifa, Arthur J. Moss, David Oakes, Jeanne Poole, Claudio Schuger, Jagmeet Singh, Scott Solomon, David Wilber, Wojciech Zareba
Journal: Journal of the American College of Cardiology (2016)
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Inflammatory Bowel Disease: A Single-Center Experience
Authors: Samantha M. Chin, Jenny Sauk, Jasmine Mahabamunuge, Jess L. Kaplan, Elizabeth L. Hohmann, Hamed Khalili
Journal: Clinical Gastroenterology and Hepatology (2016)
The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.
Authors: Franck E Nicolini, Stephane Morisset, Andreas Hochhaus, Giovanni Martinelli, Dong-Wook Kim, Inge Dufva, Michael Mauro, Jorge E. Cortes, Charles Chuah, Jane Apperley, Francois Guilhot, Giuseppe Saglio, Martin C. Müller, Simona Soverini, Selim Corm, Isabelle Tigaud, Madeleine Etienne, Catherine Roche-Lestienne, Sandrine Hayette, Senaka Peter, Wei Zhou, Mauricette Michallet
Journal: Blood (2010)
Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.
Authors: Brian K. Link, James R. Cerhan, Hildy Dillon, Charles M. Farber, Susan Feliciano, Jonathan W. Friedberg, John Hainsworth, Ron Steis, Julie M. Vose, Andrew D. Zelenetz
Journal: Blood (2005)
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Authors: Steven R. Leong, Siddharth Sukumaran, Maria Hristopoulos, Klara Totpal, Shannon Stainton, Elizabeth Lu, Alfred Wong, Lucinda Tam, Robert Newman, Brian R. Vuillemenot, Diego Ellerman, Chen Gu, Mary Mathieu, Mark S. Dennis, Allen Nguyen, Bing Zheng, Crystal Zhang, Genee Lee, Yu-Waye Chu, Rodney A. Prell, Kedan Lin, Steven T. Laing, Andrew G. Polson
Journal: Blood (2016)
Scratching Below the Surface
Authors: Susan K. Mathai, S. Andrew Josephson, Jessica Badlam, Sanjay Saint, William J. Janssen
Journal: New England Journal of Medicine (2016)

A 27-year-old woman was brought to the emergency department because of “strange behavior.” Her illness had begun 7 days earlier with nausea and palpitations and had progressed to agitation, hallucinations, intermittent muscle rigidity, and involuntary jerking of the arms and legs.
Pegylated Recombinant Murine GM-CSF Is a Potent Mobilizer of Murine Bone Marrow Progenitors, Synergizes with BIO5192 and Plerixafor (AMD3100), and Skews Mobilized Cells to a Tolerogenic Phenotype.
Authors: Mark A. Schroeder, Jonathan D. Ricks, Jaebok Choi, Julie Ritchey, Matthew Holt, Brian K. Dieckgraefe, John F. DiPersio
Journal: Blood (2009)
Founder Effects of a Recurrent Splicing Mutation IVS9-1G&gt;C of the UNC13D Gene in Korean Patients with Familial Hemophagocytic Lymphohistiocytosis
Authors: Joon Sup Song, Hee Jin Kim, Ja Young Seo, Sun Hee Kim, Ki O Lee, In Ae Park, Mee Jeong Lee, Hong Hoe Koo, Hyo Seop Ahn, Chuhl Joo Lyu, Ji Yoon Kim, Eun Sil Park, In Sang Jeon, Young Tak Lim, Bo Eun Kim, Kyung Nam Koh, Ho Joon Im, Jong Jin Seo
Journal: Blood (2011)
The PI3K Inhibitor ON 01910.Na Inhibits Critical Survival Pathways and Induces Apoptosis in CLL Cells through Induction of NOXA and BIM.
Authors: Patricia Perez Galan, Colby M Chapman, Federica Gibellini, Poching Liu, Nalini Raghavachari, Mark Roschewski, Adrian Wiestner
Journal: Blood (2009)
Identification of a Novel TEL-Lyn Fusion Gene in Chronic Eosinophilic Leukemia with ins (12;8)(p13;q11q21): Effect on Myeloproliferative Transformation and Induction of Myelofibrosis.
Authors: Hiroaki Tanaka, Masahiro Takeuchi, Yusuke Takeda, Kayo Oda, Daijiro Abe, Chikako Ohwada, Shinichi Ozawa, Emiko Sakaida, Naomi Shimizu, Ryuko Cho, Miki Nishimura, Yasushi Saito, Satoru Miyagi, Atsushi Iwama, Chiaki Nakaseko
Journal: Blood (2007)
Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis
Authors: Elisabeth Schorb, Benjamin Kasenda, Johannes Atta, Nikolas von Bubnoff, Thomas Elter, Georg Hess, Stefan W. Krause, Anke Morgner, Kaun Stephan, Kristina Fritsch, Jürgen Finke, Gerald Illerhaus
Journal: Blood (2011)
MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.
Authors: Monika Brüggemann, Thorsten Raff, Christiane Pott, Sebastian Böttcher, Matthias Ritgen, Renate Arnold, Dieter Hoelzer, Nicola Goekbuget, Michael Kneba
Journal: Blood (2007)